Catalyst Pharmaceuticals Inc’s recently made public that its Chief Op. & Scientific Officer Miller Steve unloaded Company’s shares for reported $1.1 million on Dec 10 ’24. In the deal valued at $21.93 per share,50,000 shares were sold. As a result of this transaction, Miller Steve now holds 686,996 shares worth roughly $14.6 million.
Then, Miller Steve bought 50,000 shares, generating $1,096,333 in total proceeds.
Before that, INGENITO GARY sold 12,000 shares. Catalyst Pharmaceuticals Inc shares valued at $272,654 were divested by the Chief Med. & Reg. Officer at a price of $22.72 per share. As a result of the transaction, INGENITO GARY now holds 51,391 shares, worth roughly $1.09 million.
Robert W. Baird initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to an Outperform in a research note published on February 04, 2025; the price target was $28. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid November with a ‘”an Overweight”‘ rating. Citigroup began covering CPRX with “Buy” recommendation on March 14, 2024. BofA Securities started covering the stock on March 07, 2024. It rated CPRX as “a Buy”.
Price Performance Review of CPRX
On Friday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock fall -1.71% to $21.25. Over the last five days, the stock has lost -8.68%. Catalyst Pharmaceuticals Inc shares have risen nearly 1.82% since the year began. Nevertheless, the stocks have risen 55.00% over the past one year. While a 52-week high of $24.64 was reached on 01/30/25, a 52-week low of $13.49 was recorded on 01/08/25. SMA at 50 days reached $22.19, while 200 days put it at $19.66.
Levels Of Support And Resistance For CPRX Stock
The 24-hour chart illustrates a support level at 21.03, which if violated will result in even more drops to 20.81. On the upside, there is a resistance level at 21.68. A further resistance level may holdings at 22.11. The Relative Strength Index (RSI) on the 14-day chart is 37.27, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.03, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.60%. Stochastics %K at 9.75% indicates the stock is a buying.
The most recent change occurred on December 21, 2023 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
